WINT jumps 4.87% as Windtree allocates 99% of $520M raise to BNB in treasury strategy shift

Windtree Therapeutics (WINT), a Nasdaq-listed biotechnology firm, has announced plans to raise up to $520 million through two funding agreements, with 99% of proceeds allocated to purchasing Binance Coin (BNB) as part of its strategic treasury diversification. The funding includes a $500 million equity line of credit (ELOC) and a $20 million stock purchase deal with Build and Build Corp. The biotech company’s aggressive crypto allocation mirrors its earlier $60 million BNB acquisition in July 2023 and underscores a growing trend of institutional adoption of blockchain assets in non-tech sectors [1].

The move has already triggered a 4.87% surge in WINT’s stock price to $1.02 on July 25, following a 537.5% increase over six months and a 175.6% rally in the last month alone. CEO Jed Latkin emphasized that securing shareholder approval to expand authorized shares is critical to unlocking the ELOC funds, which could enable the company to purchase up to 676,371 BNB at the current price of $761.12. Latkin stated that the strategy aims to “redefine what it means to be a forward-thinking public company in the digital age” by leveraging BNB as a strategic asset [1].

The biotech firm’s treasury strategy hinges on the assumption that blockchain-based infrastructure will increasingly shape global finance. By allocating nearly all raised capital to BNB, Windtree is positioning itself as one of the largest publicly traded companies to actively accumulate a major cryptocurrency. Analysts have noted that the success of this approach depends on broader market confidence in crypto assets and regulatory clarity. If shareholders approve the ELOC, Windtree could further diversify its reserves and explore additional funding avenues to scale its crypto holdings.

BNB’s recent performance, trading 0.15% lower at $761.12 at press time, reflects broader market volatility but has not deterred institutional interest. Windtree’s actions suggest a belief that holding BNB offers long-term strategic value, potentially offering competitive advantages in liquidity and growth. The company’s dual focus on biotech innovation and crypto treasury management highlights a hybrid model that could influence other traditional firms to explore similar strategies.

Source: [1] [title: BNB Just Got a Biotech Backer with $520 Million; Here’s What Could Happen Next] [url: https://coinmarketcap.com/community/articles/68835ca2d9d19935252ecd9b/]